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A reactive oxygen species-generating, cyclooxygenase-2 
inhibiting, cancer stem cell-potent tetranuclear copper(II) cluster  
C. Lu,a,b K. Laws,a A. Eskandari,a and K. Suntharalingama* 
Tetranuclear copper(II) complexes containing multiple diclofenac 
and Schiff base moieties, 1-4 are shown to kill bulk cancer cells 
and cancer stem cells (CSCs) with low micromolar potency. The 
most effective complex, 1 elicits its cytotoxic effect by elevating 
intracellular reactive oxygen species (ROS) levels and inhibiting 
cyclooxygenase-2 (COX-2) expression.  
Cancer stem cells (CSCs) are a distinct subpopulation of 
tumour cells that have high clonal long-term repopulation and 
self-renewal capacity.1,2 The quiescent, slow-cycling, and stem-
like properties of CSCs enable them to survive current 
therapeutic regimens (which are often designed to target 
proliferating bulk cancer cells) and instigate tumour regrowth.3 
CSCs are also linked to metastasis due to their inherent 
plasticity to reversibly transition between stem cell-like cells 
and non-stem cell-like cells.4,5 The clinical implication of CSCs 
means that cancer treatments must have the ability to remove 
heterogeneous cancer population in their entirety, including 
bulk cancer cells and CSCs, otherwise CSC-mediated relapse 
could occur. Although a great deal of effort has gone into 
identifying CSC therapeutic targets such as cell surface 
markers, organelles, dysregulated signalling pathways, and 
aspects of their microenvironment,6 there is still no clinically 
approved agent (chemical or biological) that can 
simultaneously remove bulk cancer cells and CSCs. Most of the 
CSC specific small molecules undergoing clinical trials are 
organic in nature,7 however, we and others have shown that 
metal complexes also display attractive anti-CSC and -bulk 
cancer cell properties.8-15 
 Our previous work has shown that reactive oxygen species 
(ROS) elevation in combination with cyclooxygenase-2 (COX-2) 
inhibition by mononuclear copper(II)-nonsteroidal anti-
inflammatory drug (NSAID) complexes enables CSC and bulk 
cancer cell toxicity.9,10,13 The success of this strategy is 
attributed to the vulnerability of CSCs and bulk cancer cells to 
changes in their intracellular redox state16,17 and the 
overexpression of COX-218,19 in certain CSCs and bulk cancer 
cells. Here, we have sought to improve CSC and bulk cancer 
cell activity by developing tetranuclear copper(II) complexes 
bearing multiple diclofenac moieties (a COX-2 inhibitor with 
anti-metastatic potential)20,21 and Schiff base ligands (a well-
known ROS mediator once coordinated to copper).22,23 
Specifically, four copper(II) centres, four diclofenac moieties, 
and two Schiff base ligands were used (within a single cluster) 
to modulate ROS generation power and COX-2 inhibition. 
 The tetranuclear copper(II) complexes, 1-4 were 
synthesized, as outlined in Scheme S1, by refluxing the 
appropriate Schiff base ligand, L1-4 with two equivalence of 
Cu(NO3)2·3H2O and diclofenac sodium in methanol (pH 7, 
adjusted by triethylamine) for 24 h. The complexes were 
isolated as green solids in reasonable yields (48-60%), and 
characterised by UV-Vis and infrared spectroscopy, and 
elemental analysis (see ESI). Single crystals of 1 suitable for X-
ray diffraction studies were obtained by slow diffusion of 
diethyl ether into an acetonitrile:DMF (100:1) solution of 1 
(CCDC 1548878, Fig. 1 and S1). Selected bond distances and 
bond angles data are presented in Table S1-2. The structure 
consists of four copper(II) centres, two Schiff base ligands, four 
diclofenac moieties, and two bridging hydroxyl groups. As 
 
Fig. 1 X-ray structure of a tetranuclear copper(II) complex, 1 comprising of  
four diclofenac moieties and two Schiff base ligands. Ellipsoids are shown 
at 50% probability, Cl atoms are shown in green, O in red, C in grey, N in 
dark blue, S in yellow, and Cu in light blue. H atoms and co-crystallizing 
solvent molecules have been omitted for clarity. 
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depicted in Fig. 1 and S1, Cu(1)/Cu(1A) and Cu(2)/Cu(2A) 
display different coordination environments. Cu(1)/Cu(1A) 
exhibits a five coordinate, distorted triangular bipyramid 
geometry whereas Cu(2)/Cu(2A) displays a five coordinate, 
distorted square-based pyramidal structure. The different 
copper(II) coordination environments is borne out in the 
slightly shorter distance of Cu(1)–Cu(1A) compared to Cu(1)–
Cu(2). The average Cu–O (2.01 Å), Cu–S (2.39 Å), and Cu–N 
(1.95 Å) bond distances are consistent with bond parameter 
for related copper(II) complexes.24-26  
 The stability of 1, taken a representative member of the 
tetranuclear copper(II) complexes, in biologically relevant 
solutions was assessed using UV-Vis spectroscopy and high 
resolution ESI mass spectrometry. In Tris-HCl (pH 7.4)/DMSO 
(200:1), 1 (50 µM) is moderately stable over the course of 24 h 
at 37 oC (Fig. S2). In PBS (pH 7.4)/DMSO (200:1) and sodium 
acetate (pH 5.12)/ DMSO (200:1) solutions, 1 (50 µM) is stable 
up to 4 hours at 37 oC, after which degradation is clearly 
observed (Fig. S3-4). In the presence of ascorbic acid (10 
equivalents in PBS), a cellular reductant, the absorption of 1 
(50 µM) changed markedly over the course of 24 h at 37 oC 
(Fig. S5). Specifically, the strong band at 270 nm, associated to 
ligand-centred π-π* transitions decreased and was replaced by 
a broad band at 260 nm and shoulder at 278 nm. The latter is 
reminiscent of free diclofenac (25 µM, Fig. S6). Lower energy 
bands at 320 nm and 365 nm corresponding to metal-
perturbed π-π* transitions associated to L1 (Fig. S6) also 
decreased, suggesting a possible change in the copper 
oxidation state and coordination environment. ESI mass 
spectrometry studies under the same conditions revealed 
peaks corresponding to [diclofenac+K]+ (335.0113 m/z) and 
[diclofenac-H]- (294.0097 m/z) in the positive and negative 
mode respectively (Fig. S7 and S8). This shows that diclofenac 
is released under reducing conditions. Peaks with the 
appropriate isotopic pattern, associated to mononuclear 
copper complexes with various ratios of diclofenac and L1 were 
also observed (Fig. S8 and S9), implying that 1 does not remain 
as a tetranuclear entity under reducing conditions. Upon 
incubating concentrated solutions of 1 (250 µM) with ascorbic 
acid (2.5 mM) in PBS/DMSO (95:5) for 24h at 37 oC, the d-d 
transition band (647 nm) associated to the copper(II) centre 
disappeared indicative of reduction to copper(I) (Fig. S10). This 
was further proved by the addition of bathocuproine 
disulfonate (BCS, 2 equivalence), a strong copper(I) chelator, 
which produced a characteristic absorption band at 480 nm 
corresponding to [CuI(BCS)2]3- (Fig. S11).27 Collectively the UV-
Vis and ESI mass spectrometry studies suggest that the copper 
centres in 1 are reduced from Cu(II) to Cu(I) under biologically 
relevant conditions and that diclofenac is liberated.   
 The bulk breast cancer cell (HMLER) and CSC (HMLER-
shEcad) potency of 1-4 after 72 h incubation was determined 
using the MTT [3-(4,5-di-methylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay. IC50 values 
(concentrations required to reduce cell viability by 50%) were 
determined from dose–response curves (Fig. S12-15) and are 
summarized in Table 1. All of the tetranuclear complexes, 1-4 
displayed equal toxicity towards CSC-enriched HMLER-shEcad 
cells and bulk cancer-enriched HMLER cells, in the low 
micromolar range. The advantage of 1-4 over CSC-selective 
compounds such as salinomycin (Table 1),28 is that they have 
the potential to remove whole cancer cell populations (bulk 
cancer cells and CSCs) with a single dose. CSC-selective 
compounds need to be administered in combination with bulk 
cancer-selective agents (at the appropriate dose) to elicit a 
similar response. Control cytotoxicity studies showed that the 
potency of diclofenac, CuCl2, and 1 pre-incubated with 10 
equivalents of ascorbic acid for 24 h (1 + AA, 
reduced/degradation products) towards HMLER and HMLER-
shEcad cells was significantly lower than 1 (Table 1 and Fig. 
S16-18). This suggests that the cytotoxicity of 1 is likely to 
result from intact 1 rather than its individual components 
Table 1. IC50 values of 1-4, diclofenac, CuCl2, 1 preincubated with 
10 equivalents of ascorbic acid for 24 h, and salinomycin against 
HMLER and HMLER-shEcad cells determined after 72 h incubation 
(mean of three independent experiments ± SD). a Taken from 
reference 9. 
 
Compound HMLER 
IC50 / μM  
HMLER-shEcad 
IC50 / μM  
1 8.4 ± 0.2 8.6 ± 0.3 
2 13.1 ± 0.3  14.4 ± 0.2 
3 13.0 ± 0.7 13.1 ± 0.3 
4 8.3 ± 0.5 8.4 ± 0.1 
diclofenac > 100 37.1 ± 2.0 
CuCl2 > 100 > 100 
1 + AA > 100 83.0 ± 8.9 
salinomycina 11.4 ± 0.4 4.2 ± 0.4 
 
 
Fig. 2 (A) Quantification of mammosphere formation with HMLER-
shEcad cells untreated and treated with 1-3 and salinomycin at their 
respective IC20 values for 5 days. Error bars = SD and Student t-test, * = p 
< 0.05, ** = p < 0.01. (B) Representative bright-field images (× 10) of the 
mammospheres in the absence and presence of 1 and salinomycin at 
their respective IC20 values. 
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(diclofenac and copper) or the reduced/degradation products 
(1 + AA). 
The mammosphere assay was performed to determine the 
ability of 1-3 to inhibit the formation of spheroids comprising 
of breast CSCs. This method serves as a reliable readout for 
CSC potency and in vivo potential, given that three-
dimensional systems are more representative of solid tumours 
compared to monolayer cell cultures.29 The addition of 1-3 (at 
the IC20 value) to single cell suspensions of HMLER-shEcad cells 
significantly (p < 0.05) reduced the number and size of 
mammospheres formed after 5 days incubation (Fig. 2 and 
S19). Notably, 1 displayed the highest inhibitory effect, 
reducing the number of mammospheres formed by 51% 
compared to the untreated control. This is comparable to the 
effect of salinomycin (46% reduction in mammosphere 
formed), an established mammosphere-potent agent (Fig. 2). 
Upon treatment of single cell suspensions of HMLER-shEcad 
cells with diclofenac and CuCl2 (at the IC20 value for 5 days), 
the number and size of mammospheres formed was largely 
unaffected (Fig. S20-21). The colorimetric resazurin-based 
reagent, TOX8 was used to measure the ability of 1-3 to reduce 
mammosphere viability. The IC50 values (concentration 
required to decrease mammosphere viability by 50%) of 1-3 
were in the micromolar range (Fig. S22 and Table S3). Notably, 
1 exhibited the greatest mammosphere-potency (IC50 = 27.9 ± 
1.3 µM) within the series, comparable to salinomycin (IC50 = 
18.5 ± 1.5 µM). Diclofenac and CuCl2 were relatively non-toxic 
towards mammospheres (IC50 > 133 µM, Fig. S23, Table S3). 
This suggests that mammosphere potency of 1 is likely to 
result from intact 1 rather than its individual components 
(diclofenac and copper). Overall the cytotoxicity and 
mammosphere studies show that 1-3, in particular 1, can 
effectively inhibit CSC growth in monolayer and three-
dimensional cell culture systems.  
 Cell uptake studies were conducted to identify bulk breast 
cancer cell and CSC permeability. HMLER and HMLER-shEcad 
cells were treated with 1-4 (10 µM for 24 h) and the copper 
content was determined by inductively coupled plasma mass 
spectrometry (ICP-MS). As depicted in Fig. 3 and S24, 1-4 are 
readily taken up by HMLER and HMLER-shEcad cells (> 48 ppb 
of Cu/ million cells). Strikingly, 1 displayed up to 6-fold higher 
uptake by HMLER-shEcad cells and 2-fold higher uptake by 
HMLER cells than 2-4, suggesting that the addition of the 
methoxy group on the Schiff base ligand hinders bulk cancer 
cell and CSC uptake. No direct correlation could be drawn 
between cellular uptake and bulk cancer or CSC cell 
cytotoxicity. Control cellular uptake studies showed that CuCl2 
and 1 + AA (reduced/degradation products) were taken up to a 
lesser extent than 1 by HMLER-shEcad cells under identical 
conditions (10 µM for 24 h) (Fig. S25). Diclofenac was also 
shown to not traffic large quantities of copper into HMLER-
shEcad cells (Fig. S25). This suggests that 1 is taken up better 
by CSCs as the intact cluster rather than as the 
reduced/degraded products (1 + AA). For 1, the complex with 
the greatest uptake, fractionation studies were carried out 
with HMLER-shEcad cells (treated with 10 µM for 24 h), to 
determine cell localisation (Fig. S26). A significant amount of 
internalised 1 was detected in the cytoplasm (35%). A 
relatively lower, but nevertheless appreciable amount of 1 was 
found in the nucleus (11%). The data also revealed that a large 
portion of 1 (48%) became trapped in the cell membrane. This 
is could be due to the large size and high intrinsic lipophilicity 
of 1. Overall, the fractionation studies suggest that 1-induced 
toxicity is more likely to result from deleterious action within 
the cytoplasm rather than the nucleus.  
 The tetranuclear complexes were expected to increase 
intracellular ROS levels and thereby induce cell death. To 
determine the ability of 1 to produce ROS in HMLER-shEcad 
cells, 6-carboxy-2’,7’-dichlorodihydrofluorescein diacetate 
(DCFH-DA), a well-established ROS indicator was used. HMLER-
shEcad cells treated with 1 (20 µM) displayed a noticeable 
 
Fig. 3 Copper content in HMLER-shEcad cells treated with 1-4 (10 μM for 
24 h). The copper content was determined by ICP-MS. 
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Fig. 4 (A) Normalised ROS activity in untreated HMLER-shEcad cells 
(control) and HMLER-shEcad cells treated with 1 (20 µM for 3, 6, 12, and 
24 h) and co-treated with 1 (20 µM for 3, 6, 12, and 24 h) and N-
acetylcysteine (2.5 mM for 3, 6, 12, and 24 h). Error bars represent 
standard deviations and Student t test, * = p < 0.05.  (B) Representative 
histograms displaying the green fluorescence emitted by anti-COX-2 Alexa 
Fluor 488 nm antibody-stained HMLER-shEcad cells treated with LPS (2.5 
μM) for 24 h (red) followed by 48 h in media containing 1 (5 - 15 μM, blue, 
orange, and green). (C) Representative dose-response curves for the 
treatment of HMLER-shEcad cells with 1 after 72 incubation in the 
presence and absence of PGE2 (20 μM). 
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increase in ROS levels after 3 h (17%) and 6 h (26%) exposure 
(Fig. 4A). Prolonged exposure of 1 (20 µM for 12 or 24 h) did 
not significantly increase ROS levels compared to untreated 
control cells (Fig. 4A). Therefore 1-induced ROS generation is 
time-dependent. Similar results have been reported for other 
metal complexes.30 HMLER-shEcad cells treated with H2O2 (150 
µM for 3, 6, 12, or 24 h) exhibited a marked increase in ROS 
levels (7-8-fold) relative to untreated control cells (Fig. S27). 
Notably, both 1- (after 6 and 3 h exposure) and H2O2- (after 3, 
6, 12, and 24 h exposure) induced ROS production was 
reduced in the presence of N-acetylcysteine (2.5 mM), a ROS 
scavenger (Fig. 4A and S27). Cytotoxicity studies in the 
presence of N-acetylcysteine (2.5 mM, 72 h) showed that the 
potency of 1 towards HMLER-shEcad cells decreased 
significantly (IC50 value increased from 8.6 ± 0.3 µM to 11.9 ± 
0.3 µM, p < 0.05) (Fig. S28). Taken together, this suggests that 
1-induced cell death is related to intracellular ROS generation. 
 COX-2 is overexpressed in certain cancer cells and linked to 
proliferative cancer growth and resistance against traditional 
chemotherapy and radiotherapy.31,32 There is compelling 
evidence for a role for COX-2 in CSC biology and as a mediator 
of tumour repopulation and metastasis.18,32 Given these 
findings, COX-2 is now recognised as a molecular target for 
CSC-directed therapy. As the tetranuclear complex, 1 contains 
four diclofenac moieties which can potentially be released 
under biologically reducing conditions, flow cytometric studies 
were performed to determine if the mechanism of action of 1 
involved COX-2 downregulation. Upon treatment of HMLER-
shEcad cells pre-treated with lipopolysaccharide (LPS) (2.5 μM 
for 24 h), to increase basal COX-2 levels, with 1 (5-15 μM for 
48 h), a marked decrease in COX-2 expression compared to 
untreated cells was observed (Fig. 4B). A decrease in COX-2 
expression was also observed in HMLER-shEcad cells treated 
with diclofenac (20 μM for 48 h) (Fig. S29). Overall, the flow 
cytometric data suggests that the cytotoxic mechanism of 
action of 1 may involve COX-2 downregulation. To prove this, 
cytotoxicity studies were carried out with HMLER-shEcad in 
the presence and absence of prostaglandin E2 (PGE2) (20 μM, 
72 h), the functional product of COX-2-catalysed arachidonic 
acid metabolism. The IC50 value of 1 against HMLER-shEcad 
cells decreased by 3.8-fold in the presence of PGE2 (Fig. 4C), 
implying that 1 induces COX-2-dependent CSC death. 
 In summary, we report the first tetranuclear copper(II) 
complexes, 1-4 to simultaneously kill bulk cancer and CSCs. As 
1-4 are equipotent towards bulk cancer cells and CSCs, they 
have the potential to remove heterogenous tumour 
populations with a single dose. The representative complex, 1 
is readily taken up by CSCs and induces cell death by 
generating intracellular ROS and downregulating COX-2 
expression. Our results pave the way for the development of 
other multinuclear metal complexes (bearing various 
biologically active moieties) that can evoke bulk cancer and 
CSC death through distinct cellular pathways. 
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Experimental Details 
 
Materials and Methods. All synthetic procedures were performed under normal atmospheric 
conditions. Fourier transform infrared (FTIR) spectra were recorded with a IRAffinity-1S 
Shimadzu spectrophotometer. High resolution electron spray ionisation mass spectra were 
recorded on a BrukerDaltronics Esquire 3000 spectrometer by Dr. Lisa Haigh (Imperial 
College London). UV-Vis absorption spectra were recorded on a Cary100 UV-Vis 
spectrophotometer. For the UV studies, a 10 mM stock solution of 1 in DMSO was initially 
prepared. The copper concentration of the stock solution was determined by inductively 
coupled plasma mass spectrometry (ICP-MS, PerkinElmer NexION 350D). The stock 
solution was then diluted in the appropriate solution to the working concentration. Elemental 
analysis of the compounds prepared was performed commercially by London Metropolitan 
University. The Schiff based ligands, L1-4 were prepared according to previously reported 
protocols.1  
 
Synthesis of Cu4(diclofenac)4(L1)2 (1). Diclofenac sodium (190.9 mg, 0.6 mmol) in 
methanol (10 mL) was added dropwise to a mixture of L1 (58.5 mg, 0.3 mmol) and 
Cu(NO3)2·3H2O (144 mg, 0.6 mmol) in methanol (10 mL). The pH was adjusted to 7 using 
triethylamine and the solution was refluxed for 24 h. The resulting precipitate was filtered 
and thoroughly washed with water (3 x 10 mL) and diethyl ether (3 x 10 mL). The 
tetranuclear copper(II) complex, 1 was isolated as a green solid (171 mg, 60%). IR (solid, cm-
1): 1620, 1614, 1597, 1578, 1540, 1505, 1466, 1448, 1395, 1362, 1308, 1268, 1196, 1147, 
1130, 1069, 1029, 944, 766, 741, 718, 603 (Cu-O), 573, 528, 467 (Cu-O), 441 (Cu-O); UV 
(acetonitrile, nm): 275, 323, 377; Anal. Calcd. for 1, C76H66Cl8Cu4N6O12S2: C, 49.15; H, 
3.58; N, 4.52. Found: C, 49.15; H, 3.23; N, 4.75. 
 
Synthesis of Cu4(diclofenac)4(L2)2 (2). Diclofenac sodium (190.9 mg, 0.6 mmol) in 
methanol (10 mL) was added dropwise to a mixture of L2 (67.5 mg, 0.3 mmol) and 
Cu(NO3)2·3H2O (144 mg, 0.6 mmol) in methanol (10 mL). The pH was adjusted to 7 using 
triethylamine and the solution was refluxed for 24 h. The resulting precipitate was filtered 
and thoroughly washed with water (3 x 10 mL) and diethyl ether (3 x 10 mL). The 
tetranuclear copper(II) complex, 1 was isolated as a green solid (137 mg, 48%). IR (solid, cm-
1): 1622, 1495, 1449, 1394, 1281, 1034, 1022, 1015, 775, 768, 743, 718, 704, 660, 609 (Cu-
O), 534, 472 (Cu-O), 451 (Cu-O); UV (acetonitrile, nm): 277, 453; Anal. Calcd. for 
compound 2, C78H70Cl8Cu4N6O14S2: C, 48.86; H, 3.68; N, 4.38. Found: C, 48.80; H, 3.57; N, 
4.25. 
 
Synthesis of Cu4(diclofenac)4(L3)2 (3). Diclofenac sodium (190.9 mg, 0.6 mmol) in 
methanol (10 mL) was added dropwise to a mixture of L3 (67.5 mg, 0.3 mmol) and 
Cu(NO3)2·3H2O (144 mg, 0.6 mmol) in methanol (10 mL). The pH was adjusted to 7 using 
triethylamine and the solution was refluxed for 24 h. The resulting precipitate was filtered 
and thoroughly washed with water (3 x 10 mL) and diethyl ether (3 x 10 mL). The 
tetranuclear copper(II) complex, 1 was isolated as a green solid (158 mg, 57%). IR (solid, cm-
1): 1609, 1577, 1562, 1534, 1502, 1444, 1369, 1220, 1124, 769, 744, 619 (Cu-O), 577, 532, 
469 (Cu-O), 444 (Cu-O); UV (acetonitrile, nm): 285, 321, 363; Anal. Calcd. for compound 3, 
C78H70Cl8Cu4N6O14S2: C, 48.86; H, 3.68; N, 4.38. Found: C, 48.82; H, 3.51; N, 4.25.     
 
Synthesis of Cu4(diclofenac)4(L4)2 (4). Diclofenac sodium (190.9 mg, 0.6 mmol) in 
methanol (10 mL) was added dropwise to a mixture of L4 (67.5 mg, 0.3 mmol) and 
Cu(NO3)2·3H2O (144 mg, 0.6 mmol) in methanol (10 mL). The pH was adjusted to 7 using 
triethylamine and the solution was refluxed for 24 h. The resulting precipitate was filtered 
and thoroughly washed with water (3 x 10 mL) and diethyl ether (3 x 10 mL). The 
tetranuclear copper(II) complex, 1 was isolated as a green solid (155 mg, 54%). IR (solid, cm-
1): 1622, 1494, 1449, 1391, 1283, 1034, 1015, 768, 741, 718, 660, 609 (Cu-O), 533, 472 (Cu-
O), 442 (Cu-O); UV (acetonitrile, nm): 276, 454; Anal. Calcd. for compound 4, 
C78H70Cl8Cu4N6O14S2: C, 48.86; H, 3.68; N, 4.38. Found: C, 48.77; H, 3.64; N, 4.27. 
 
X-ray Single Crystal Diffraction Analysis. Standard procedures were used to mount the 
crystal on a Gemini diffractometer with graphite-monochromated Mo Kα radiation (λ = 
0.71073 Å) at 293 K. The crystal structure was solved using direct methods in SHELXS and 
refined by full-matrix least-squares routines, based on F2, using the SHELXL program.2 All 
the H atoms were placed in geometrically idealised positions and constrained to ride on their 
parent atoms. The structure has been deposited with the Cambridge Crystallographic Data 
Centre (CCDC 1548878). This information can be obtained free of charge from 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Cell Lines and Cell Culture Conditions. The human mammary epithelial cell lines, 
HMLER and HMLER-shEcad were kindly donated by Prof. R. A. Weinberg (Whitehead 
Institute, MIT). HMLER and HMLER-shEcad cells were maintained in Mammary Epithelial 
Cell Growth Medium (MEGM) with supplements and growth factors (BPE, hydrocortisone, 
hEGF, insulin, and gentamicin/amphotericin-B). The cells were grown at 310 K in a 
humidified atmosphere containing 5% CO2. 
 
Cytotoxicity MTT assay. The colourimetric MTT assay was used to determine the toxicity 
of 1-4. HMLER or HMLER-shEcad (5 × 103) were seeded in each well of a 96-well plate. 
After incubating the cells overnight, various concentrations of the compounds (0.2-100 µM), 
were added and incubated for 72 h (total volume 200 µL). Stock solutions of the compounds 
were prepared as 10 mM solutions in DMSO and diluted using media. The final 
concentration of DMSO in each well was 0.5% and this amount was present in the untreated 
control as well. After 72 h, 20 μL of a 4 mg/mL solution of MTT in PBS was added to each 
well, and the plate was incubated for an additional 4 h. The MEGM/MTT mixture was 
aspirated and 200 μL of DMSO was added to dissolve the resulting purple formazan crystals. 
The absorbance of the solutions in each well was read at 550 nm. Absorbance values were 
normalized to (DMSO-containing) control wells and plotted as concentration of test 
compound versus % cell viability. IC50 values were interpolated from the resulting dose 
dependent curves. The reported IC50 values are the average of three independent experiments, 
each consisting of six replicates per concentration level (overall n = 18). 
 
Tumorsphere Formation and Viability Assay. HMLER-shEcad cells (5 × 103) were plated 
in ultralow-attachment 96-well plates (Corning) and incubated in MEGM supplemented with 
B27 (Invitrogen), 20 ng/mL EGF, and 4 µg/mL heparin (Sigma) for 5 days. Studies were 
conducted in the absence and presence of 1-3 and salinomycin. Mammospheres treated with 
1-3 and salinomycin (at their respective IC20 values, 5 days) were counted and imaged using 
an inverted microscope. The viability of the mammospheres was determined by addition of a 
resazurin-based reagent, TOX8 (Sigma). After incubation for 16 h, the solutions were 
carefully transferred to a black 96-well plate (Corning), and the fluorescence of the solutions 
was read at 590 nm (λex = 560 nm). Viable mammospheres reduce the amount of the oxidized 
TOX8 form (blue) and concurrently increases the amount of the fluorescent TOX8 
intermediate (red), indicating the degree of mammosphere cytotoxicity caused by the test 
compound. Fluorescence values were normalized to DMSO-containing controls and plotted 
as concentration of test compound versus % mammospheres viability. IC50 values were 
interpolated from the resulting dose dependent curves. The reported IC50 values are the 
average of two independent experiments, each consisting of three replicates per concentration 
level (overall n = 6). 
 
Cellular Uptake. To measure the cellular uptake of 1-4 ca. 1 million HMLER and HMLER-
shEcad cells were treated with 1-4 (10 μM) at 37 ºC for 24 h. After incubation, the media was 
removed, the cells were washed with PBS (2 mL × 3), harvested, and centrifuged. The 
cellular pellets were dissolved in 65% HNO3 (250 μL) overnight. For 1, cellular pellets were 
also used to determine the copper content in the nuclear, cytoplasmic, and membrane 
fractions. The Thermo Scientific NE-PER Nuclear and Cytoplasmic Extraction Kit were used 
to extract and separate the nuclear, cytoplasmic, and membrane fractions. The fractions were 
dissolved in 65% HNO3 overnight (250 μL final volume). All samples were diluted 5-fold 
with water and analysed using inductively coupled plasma mass spectrometry (ICP-MS, 
PerkinElmer NexION 350D). Copper levels are expressed as Cu (ppb) per million cells. 
Results are presented as the mean of five determinations for each data point. 
 
Intracellular ROS Assay. HMLER-shEcad cells (5 × 103) were seeded in each well of a 96-
well plate. After incubating the cells overnight, they were treated with 1 or H2O2 (20 and 150 
µM for 3, 6, 12, and 24 h), in the presence or absence of N-acetylcysteine (2.5 mM), and 
incubated with 6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (20 μM) for 30 min. The 
intracellular ROS level was determined by measuring the fluorescence of the solutions in 
each well at 529 nm (λex = 504 nm). 
 
Flow cytometry. HMLER-shEcad cells were seeded in 6-well plates (at a density of 5 × 105 
cells/ mL) and the cells were allowed to attach overnight. The cells were treated with 
lipopolysaccharide (LPS) (2.5 μM for 24 h), and then treated with 1 (5-15 μM) or diclofenac 
(20 μM) and incubated for a further 48 h. The cells were then harvested by trypsinization, 
fixed with 4% paraformaldehyde (at 37 oC for 10 min), permeabilized with ice-cold methanol 
(for 30 min), and suspended in PBS (200 μL). The Alexa Fluor® 488 nm labelled anti-COX-
2 antibody (5 μL) was then added to the cell suspension and incubated in the dark for 1 hr. 
The cells were then washed with PBS (1 mL) and analysed using a FACSCanto II flow 
cytometer (BD Biosciences) (10,000 events per sample were acquired). The FL1 channel was 
used to assess COX-2 expression. Cell populations were analysed using the FlowJo software 
(Tree Star). 
 
 
 
 Scheme S1. The reaction scheme for the preparation of tetranuclear copper(II) complexes, 1-
4 comprising of four diclofenac moieties and two Schiff base ligands. 
 
 
 
Fig. S1 Crystal structure of compound 1 (ellipsoid thermal probability was drawn at the level 
of 50%, hydrogen atoms and co-crystallizing solvent molecules were omitted for clarity). 
 
 
Table S1. Crystallographic data of 1•2(C3H6NO)•2(C2H3N). 
1•2(C3H6NO)•2(C2H3N) 
Moiety formula C76H66Cl8Cu4N6O12S2•2(C3H6NO)•2(C2H3N) 
Sum formula C86H84 Cl8Cu4N10O14S2 
Fw 2083.51 
crystal system Monoclinic 
space group P 1 21/n 1 
a, Å 17.1514(3) 
b, Å 12.63396(19) 
c, Å 21.6626(4) 
α, deg. 90 
β, deg. 98.2803(15) 
γ, deg. 90 
V, Å3 4645.13(13) 
Z 2 
Dcalcd, Mg/m
3 1.490 
Reflections collected 18925 
Reflections independent (Rint) 8987 (0.0314) 
Goodness-of-fit on F2 1.027 
R(I> 2σI) 0.0472, 0.1246 
 
 
 
 
Table S2. Selected bond lengths (Å) and angles (°) for 1•2(C3H6NO)•2(C2H3N). 
Cu(1)-Cu(1A) 3.0057(7) Cu(1)-O(2A) 1.9836(18) 
Cu(1)-O(2) 1.9831(18) Cu(1)-Cu(2) 3.0536(5) 
Cu(1)-O(1) 2.366(2) Cu(1)-O(3) 1.9586(19) 
Cu(1)-O(5) 1.940(2) O(2)-Cu(1A) 1.9837(18) 
O(2)-Cu(2) 1.9728(18) Cu(2)-S(1) 2.3914(9) 
Cu(2)-O(1) 1.931(2) Cu(2)-O(6) 2.295(2) 
Cu(2)-N(1) 1.952(2) Cu(1A)-Cu(1)-Cu(2) 66.887(15) 
O(2)-Cu(1)-Cu(1A) 40.74(5) O(2A)-Cu(1)-Cu(1A) 40.73(5) 
O(2)-Cu(1)-O(2A) 81.47(8) O(2A)-Cu(1)-Cu(2) 100.27(5) 
O(2)-Cu(1)-Cu(2) 39.35(5) O(2A)-Cu(1)-O(1) 91.12(8) 
O(2)-Cu(1)-O(1) 73.48(7) O(1)-Cu(1)-Cu(1A) 79.93(6) 
O(1)-Cu(1)-Cu(2) 39.22(5) O(3)-Cu(1)-Cu(1A) 137.44(6) 
O(3)-Cu(1)-O(2) 175.87(8) O(3)-Cu(1)-O(2A) 96.83(8) 
O(3)-Cu(1)-Cu(2) 144.77(6) O(3)-Cu(1)-O(1) 110.39(8) 
O(5)-Cu(1)-Cu(1A) 132.05(7) O(5)-Cu(1)-O(2A) 162.77(9) 
O(5)-Cu(1)-O(2) 93.43(8) O(5)-Cu(1)-Cu(2) 85.55(6) 
O(5)-Cu(1)-O(1) 103.27(9) O(5)-Cu(1)-O(3) 87.12(9) 
Cu(1)-O(2)-Cu(1A) 98.53(8) Cu(2)-O(2)-Cu(1A) 115.15(9) 
Cu(2)-O(2)-Cu(1) 101.05(8) O(2)-Cu(2)-Cu(1) 39.60(5) 
O(2)-Cu(2)-S(1) 94.33(6) O(2)-Cu(2)-O(6) 89.13(7) 
S(1)-Cu(2)-Cu(1) 129.32(2) O(1)-Cu(2)-Cu(1) 50.79(6) 
O(1)-Cu(2)-O(2) 84.29(8) O(1)-Cu(2)-S(1) 176.04(7) 
O(1)-Cu(2)-O(6) 90.63(9) O(1)-Cu(2)-N(1) 93.74(11) 
O(6)-Cu(2)-Cu(1) 71.81(5) O(6)-Cu(2)-S(1) 93.06(6) 
N(1)-Cu(2)-Cu(1) 141.80(8) N(1)-Cu(2)-O(2) 172.00(10) 
N(1)-Cu(2)-S(1) 87.12(9) N(1)-Cu(2)-O(6) 98.66(9) 
 
 Fig. S2 UV-Vis spectrum of 1 (50 μM) in Tris-HCl (pH 7.4)/DMSO (200:1) over the course 
of 24 h at 37 oC. 
 
 
 
 
Fig. S3 UV-Vis spectrum of 1 (50 μM) in PBS (pH 7.4)/DMSO (200:1) over the course of 24 
h at 37 oC. 
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Fig. S4 UV-Vis spectrum of 1 (50 μM) in sodium acetate buffer (pH 5.12)/DMSO (200:1) 
over the course of 24 h at 37 oC. 
 
 
 
 
 
 
Fig. S5 UV-Vis spectrum of 1 (50 μM) in the presence of ascorbic acid (500 μM) in PBS (pH 
7.4)/DMSO (200:1) over the course of 24 h at 37 oC.  
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Fig. S6 UV-Vis spectrum of L1 (50 μM), L1 (50 μM) + CuI (50 μM), diclofenac (25 μM) in 
PBS (pH 7.4)/DMSO (200:1) at 37 oC.  
 
 
Fig. S7. ESI mass spectrum (positive mode, 150-650 m/z) of 1 (50 μM) in PBS (pH 
7.4)/DMSO (200:1), in the presence of ascorbic acid (0.5 mM) after 24 h at 37 oC. 
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 Fig. S8. ESI mass spectrum (negative mode, 100-650 m/z) of 1 (50 μM) in PBS (pH 
7.4)/DMSO (200:1), in the presence of ascorbic acid (0.5 mM) after 24 h at 37 oC. 
 
 
Fig. S9. ESI mass spectrum (negative mode, 400-2200 m/z) of 1 (50 μM) in PBS (pH 
7.4)/DMSO (200:1), in the presence of ascorbic acid (0.5 mM) after 24 h at 37 oC. 
 Fig. S10 UV-Vis spectrum of 1 (250 μM) in the presence of ascorbic acid (2.5 mM) in PBS 
(pH 7.4)/DMSO (95:5) over the course of 24 h at 37 oC. 
 
 
 
Fig. S11 UV-Vis spectrum of 1 (50 μM) in the presence of ascorbic acid (500 μM) and 
bathocuproine disulfonate, BCS (100 μM) in PBS (pH 7.4)/DMSO (200:1) over the course of 
24 h at 37 oC. 
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Fig. S12 Representative dose-response curves for the treatment of HMLER and HMLER-
shEcad cells with 1 after 72 h incubation. 
 
 
 
Fig. S13 Representative dose-response curves for the treatment of HMLER and HMLER-
shEcad cells with 2 after 72 h incubation. 
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Fig. S14 Representative dose-response curves for the treatment of HMLER and HMLER-
shEcad cells with 3 after 72 h incubation. 
 
 
 
Fig. S15 Representative dose-response curves for the treatment of HMLER and HMLER-
shEcad cells with 4 after 72 h incubation. 
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 Fig. S16 Representative dose-response curves for the treatment of HMLER and HMLER-
shEcad cells with diclofenac after 72 h incubation. 
 
 
Fig. S17 Representative dose-response curves for the treatment of HMLER and HMLER-
shEcad cells with CuCl2 after 72 h incubation. 
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 Fig. S18 Representative dose-response curves for the treatment of HMLER and HMLER-
shEcad cells with 1 pre-incubated with 10 equivalents of ascorbic acid for 24 h after 72 h 
incubation. 
 
 
 
Fig. S19 Representative bright-field images (× 10) of HMLER-shEcad mammospheres in the 
absence and presence of 2 and 3 at their respective IC20 values for 5 days. 
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 Fig. S20 Quantification of mammosphere formation with HMLER-shEcad cells untreated and treated 
with diclofenac and CuCl2 at their respective IC20 values for 5 days.  
 
 
 
 
 
Fig. S21 Representative bright-field images (× 10) of HMLER-shEcad mammospheres in the 
absence and presence of diclofenac and CuCl2 at their respective IC20 values for 5 days. 
 
 
 
 
 
 
 
 
Fig. S22 Representative dose-response curves for the treatment of HMLER-shEcad 
mammospheres with 1-3 and salinomycin after 5 days incubation. 
 
 
Fig. S23 Representative dose-response curves for the treatment of HMLER-shEcad 
mammospheres with diclofenac and CuCl2 after 5 days incubation. 
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Table S3. IC50 values of 1-3, salinomycin, diclofenac, and CuCl2 against HMLER-shEcad 
mammospheres determined after 5 days incubation (mean of three independent experiments ± 
SD).  
 
Compound Mammosphere 
IC50 [μM]  
1 27.9 ± 1.3 
2 62.5 ± 0.6 
3 36.3 ± 0.5 
diclofenac > 133.3 
CuCl2 > 133.3 
salinomycin 18.5 ± 1.5 
 
 
 
 
 
 
Fig. S24 Copper content in HMLER cells treated with 1-4 (10 μM for 24 h). 
 
 Fig. S25 Copper content in HMLER-shEcad cells treated with diclofenac, CuCl2, and 1 pre-
incubated with 10 equivalents of ascorbic acid for 24 h (10 μM for 24 h). 
 
 
 
Fig. S26 Copper content in whole cell, cytoplasm, and nucleus fractions isolated from 
HMLER-shEcad cells treated with 1 (10 µM for 24 h).  
 
 
Fig. S27 Normalised ROS activity in untreated HMLER-shEcad cells (control) and HMLER-
shEcad cells treated with H2O2 (150 µM for 3, 6, 12, and 24 h) and co-treated with H2O2 (150 
µM for 3, 6, 12, and 24 h) and N-acetylcysteine (2.5 mM for 3, 6, 12, and 24 h). Error bars 
represent standard deviations and Student t test, ** = p < 0.01. 
 
 
 
 
Fig. S28 Representative dose-response curves for the treatment of HMLER-shEcad cells with 
1 after 72 incubation in the presence and absence of N-acetylcysteine (2.5 mM ). 
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Fig. S29 Representative histograms displaying the green fluorescence emitted by anti-COX-2 
Alexa Fluor 488 nm antibody-stained HMLER-shEcad cells treated with LPS (2.5 μM) for 24 
h (red) followed by 48 h in media containing diclofenac (20 μM, blue). 
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